Life science analytics
We analyze value — you create it.
Eval.bio partners with management teams, boards, and investors to deliver robust market analyses, valuations, and due diligence that stand up to scrutiny — with clarity stakeholders can act on.
Primary focus
Search, diligence, and strategic fit
Where we go deepest: helping you find the right opportunities, stress-test them early, and decide how they fit your strategy.
- Scouting
Search & evaluation
Innovation and partnership scouting grounded in science and commercial reality — from landscape scans to prioritized opportunity shortlists.
- Validate
Initial due diligence
Rapid validation of what drives opportunity value: evidence, risks, and gaps — so you invest time and capital where it matters.
- Align
Strategic fit evaluation
Alignment of assets, portfolios, and partnerships with your strategic outcomes — clear rationale for go / no-go and next steps.
Also available
Valuation, markets, and communications
Full-spectrum support when you need investment-grade analysis and materials that align with reality — and land with stakeholders.
Valuation & forecasting
- Pharma asset valuation
- NPV & rNPV
- Scenario planning & sensitivity
- Portfolio decision-making
Market analysis
- Market sizing
- Competitive landscape
- Segmentation & positioning
- Revenue forecasting
Communications & tools
- Investment memorandums
- Pitch decks & corporate presentations
- Data visualization
- Workshops & courses
People
Science, finance, and communication — one team
We combine life science R&D understanding with entrepreneurial finance and business development to support your path to value creation.
Lead analyst
Sebastian Soidinsalo
Experienced analyst and life science communicator — market opportunities, asset valuations, and deals across therapy areas and modalities. Known for corporate narratives that unlock financing.
MBA in Biobusiness · MSc Drug Discovery